Search En menu en ClientConnect
Search
Results
Top 5 search results See all results Advanced search
Top searches
Most visited pages

    Signature(s)

    Amount
    € 115,000,000
    Countries
    Sector(s)
    Poland : € 24,150,000
    Denmark : € 90,850,000
    Industry : € 115,000,000
    Signature date(s)
    27/10/2022 : € 24,150,000
    27/10/2022 : € 90,850,000
    Link to source

    Summary sheet

    Release date
    18 November 2022
    Status
    Reference
    Signed | 27/10/2022
    20220389
    Project name
    Promoter - financial intermediary
    DEMANT MEDICAL TECHNOLOGY RDI
    DEMANT A/S
    Proposed EIB finance (Approximate amount)
    Total cost (Approximate amount)
    EUR 115 million
    EUR 240 million
    Location
    Sector(s)
    Description
    Objectives

    The project will finance the promoter's research development and innovation (RDI) investments to develop new technology hearing aids.

    The RDI activities focus on innovative solutions in hearing and acoustic technology.

    Additionality and Impact


    The project concerns RDI investments of innovative company Demant, based in Denmark and leading innovation within hearing and acoustic devices. The promoter is a knowledge-based technological company focusing on developing novel innovative hearing and audio devices targeting unmet needs with high socio-economic impact. The project builds on a regional cluster of excellence in hearing aid technology based around Copenhagen. The company's R&D intensity above sector average contributes positively towards the EU's 3% R&D intensity target. EIB's involvement will help to ensure that the important benefits of bringing novel hearing aid solutions entailed under this project come to fruition in a timely manner. The products and services developed as a result of the project will improve the possibilities of social inclusion of people suffering from hearing disabilities, therefore the social value of the project is considered to be positive and over and above the financial return.


    EIB's contribution to the project stems from the combination of a financial advantage, flexible terms of the loan, and helping to crowd-in other financiers, thereby facilitating its full financing and implementation.

    Environmental aspects
    Procurement

    The RDI activities are expected to be carried out in existing facilities that are already used for the same purposes and that are not expected to change their scope due to the project. An environmental impact assessment (EIA) is therefore not needed as per EIA Directive 2014/52/EU amending Directive 2011/92/EU. The full environmental details will however be investigated by the Bank's services during the project due diligence.

    The promoter has been assessed by the EIB as being a private company not subject to EU rules on public procurement or concessions. However, if at the project appraisal, the EIB were to conclude that it is subject to EU public procurement legislation then the promoter will have to comply to those rules and the European Commission will be informed accordingly.

    Link to source

    Disclaimer

    Before financing approval by the Board of Directors, and before loan signature, projects are under appraisal and negotiation. The information and data provided on this page are therefore indicative.
    They are provided for transparency purposes only and cannot be considered to represent official EIB policy (see also the Explanatory notes).

    Documents

    Environmental and Social Data Sheet (ESDS) - DEMANT MEDICAL TECHNOLOGY RDI
    Publication Date
    27 Oct 2022
    Document language
    Main Topic
    Lending
    Document Number
    158758950
    Document Focus
    Environmental Information
    Project Number
    20220389
    Sector(s)
    Regions
    Countries
    Publicly available
    Download now

    News & Stories

    General enquiries and comments

    The EIB is committed to open communication and encourages constructive stakeholder input regarding its activities.
    Enquiries and comments concerning the EIB’s involvement in a project or the financing facilities, activities, organisation and objectives of the EIB, can be sent to the EIB Infodesk.
    Alternatively, the EIB can be contacted through its external offices.
    Queries regarding details of a specific project, in particular when it is under appraisal by the EIB, should preferably be addressed directly to project promoters.

    Media enquiries

    Media-related enquiries can be addressed to the EIB Press Office. Please also visit our Media information section.

    Complaints mechanism

    Any complaint regarding alleged maladministration can be lodged via the EIB Complaints Mechanism. The European Ombudsman acts as an independent external accountability mechanism of the EIB.

    Zero tolerance against fraud and corruption

    The EIB has a zero tolerance policy on fraud or corruption. To report allegations of fraud and corruption relating to EIB-financed projects, please contact the Fraud and Investigation division. All complaints will be treated as strictly confidential and handled in line with the EIB investigation procedures and the Anti-Fraud Policy.

    Related publications